ResearcherUniversity of California, Los AngelesActive in the last 2 years
Jonathan C. King
Matched on ORCID iD 0009-0006-7144-3214; OpenAlex author ID A5042621306. Sources: OpenAlex.
Their work
- Papers
- 12 (first author 2, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 44
2011: 2 papers · 2012: 2 papers · 2013: 1 paper · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper · 2025: none · 2026: 2 papers
Papers 12
- Neoadjuvant stereotactic body vs conventionally fractionated radiation therapy for borderline resectable and locally advanced pancreatic cancer: a propensity s… Co-author DOI 10.1016/j.gassur.2026.102358↗
- Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase 1 trial. Co-author DOI 10.1038/s41467-026-68976-2↗
- Neoadjuvant chemotherapy is associated with improved disease-free survival in pancreatic cancer patients undergoing pancreaticoduodenectomy with vascular resec… Co-author DOI 10.1002/jso.27674↗
- Poorly differentiated histologic grade correlates with worse survival in SMAD4 negative pancreatic adenocarcinoma patients. First author DOI 10.1002/jso.26279↗
- Emerging Evidence for the Clinical Relevance of Pancreatic Cancer Exosomes. Last author DOI 10.1097/mpa.0000000000001203↗
- Deficiency in hormone-sensitive lipase accelerates the development of pancreatic cancer in conditional KrasG12D mice. Co-author DOI 10.1186/s12885-018-4713-y↗
- Deviations from Expected Treatment of Pancreatic Cancer in Octogenarians: Analysis of Patient and Surgeon Factors. Co-author DOI 10.1245/s10434-016-5456-0↗
- The flavonoid quercetin inhibits pancreatic cancer growth in vitro and in vivo. Co-author DOI 10.1097/mpa.0b013e318264ccae↗
- Evidence for activation of mutated p53 by apigenin in human pancreatic cancer. Co-author DOI 10.1016/j.bbamcr.2011.12.008↗
- Apigenin inhibits NNK-induced focal adhesion kinase activation in pancreatic cancer cells. Co-author DOI 10.1097/mpa.0b013e31824d64d9↗
- Overexpression of CXCL5 is associated with poor survival in patients with pancreatic cancer. First author DOI 10.1016/j.ajpath.2010.11.058↗
- Baicalein, a component of Scutellaria baicalensis, induces apoptosis by Mcl-1 down-regulation in human pancreatic cancer cells. Co-author DOI 10.1016/j.bbamcr.2011.05.003↗
Closest collaborators
The 25 strongest of 44 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Oscar Joe Hines · 10 shared papers, 2011–2026 · strength 0.92
- Paper Neoadjuvant stereotactic body vs conventionally fractionated radiation therapy for borderline resectable and locally ad… DOI 10.1016/j.gassur.2026.102358↗
- Paper Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase… DOI 10.1038/s41467-026-68976-2↗
- Paper Emerging Evidence for the Clinical Relevance of Pancreatic Cancer Exosomes. DOI 10.1097/mpa.0000000000001203↗
- Timothy R. Donahue · 4 shared papers, 2021–2026 · strength 0.79
- Paper Neoadjuvant chemotherapy is associated with improved disease-free survival in pancreatic cancer patients undergoing pan… DOI 10.1002/jso.27674↗
- Paper Neoadjuvant stereotactic body vs conventionally fractionated radiation therapy for borderline resectable and locally ad… DOI 10.1016/j.gassur.2026.102358↗
- Paper Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase… DOI 10.1038/s41467-026-68976-2↗
- Mark D. Girgis · 4 shared papers, 2021–2026 · strength 0.79
- Paper Neoadjuvant chemotherapy is associated with improved disease-free survival in pancreatic cancer patients undergoing pan… DOI 10.1002/jso.27674↗
- Paper Neoadjuvant stereotactic body vs conventionally fractionated radiation therapy for borderline resectable and locally ad… DOI 10.1016/j.gassur.2026.102358↗
- Paper Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase… DOI 10.1038/s41467-026-68976-2↗
- Zev A. Wainberg · 3 shared papers, 2021–2026 · strength 0.56
- Paper Neoadjuvant stereotactic body vs conventionally fractionated radiation therapy for borderline resectable and locally ad… DOI 10.1016/j.gassur.2026.102358↗
- Paper Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase… DOI 10.1038/s41467-026-68976-2↗
- Paper Poorly differentiated histologic grade correlates with worse survival in SMAD4 negative pancreatic adenocarcinoma patie… DOI 10.1002/jso.26279↗
- Jason M. Link · 2 shared papers, 2026 · strength 0.44
- Paper Neoadjuvant stereotactic body vs conventionally fractionated radiation therapy for borderline resectable and locally ad… DOI 10.1016/j.gassur.2026.102358↗
- Paper Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase… DOI 10.1038/s41467-026-68976-2↗
- David W. Dawson · 3 shared papers, 2011–2026 · strength 0.36
- Paper Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase… DOI 10.1038/s41467-026-68976-2↗
- Paper Poorly differentiated histologic grade correlates with worse survival in SMAD4 negative pancreatic adenocarcinoma patie… DOI 10.1002/jso.26279↗
- Paper Overexpression of CXCL5 is associated with poor survival in patients with pancreatic cancer. DOI 10.1016/j.ajpath.2010.11.058↗
- Guido Eibl · 7 shared papers, 2011–2019 · strength 0.36
- Paper Emerging Evidence for the Clinical Relevance of Pancreatic Cancer Exosomes. DOI 10.1097/mpa.0000000000001203↗
- Paper Deficiency in hormone-sensitive lipase accelerates the development of pancreatic cancer in conditional KrasG12D mice. DOI 10.1186/s12885-018-4713-y↗
- Paper The flavonoid quercetin inhibits pancreatic cancer growth in vitro and in vivo. DOI 10.1097/mpa.0b013e318264ccae↗
- Michael A. Mederos · 2 shared papers, 2021–2024 · strength 0.36
- Joon Y. Park · 2 shared papers, 2021–2024 · strength 0.36
- Howard A. Reber · 6 shared papers, 2011–2021 · strength 0.27
- Paper Poorly differentiated histologic grade correlates with worse survival in SMAD4 negative pancreatic adenocarcinoma patie… DOI 10.1002/jso.26279↗
- Paper The flavonoid quercetin inhibits pancreatic cancer growth in vitro and in vivo. DOI 10.1097/mpa.0b013e318264ccae↗
- Paper Apigenin inhibits NNK-induced focal adhesion kinase activation in pancreatic cancer cells. DOI 10.1097/mpa.0b013e31824d64d9↗
- Dustin L. Dillon · 1 shared paper, 2024 · strength 0.23
- William Reece Burns · 1 shared paper, 2026 · strength 0.23
- Theodore Sunki Hong · 1 shared paper, 2026 · strength 0.23
- Carlos Fernández-del Castillo · 1 shared paper, 2026 · strength 0.23
- Jin He · 1 shared paper, 2026 · strength 0.23
- Shimpei Maeda · 1 shared paper, 2026 · strength 0.23
- Takayuki Shimizu · 1 shared paper, 2026 · strength 0.23
- Motaz Qadan · 1 shared paper, 2026 · strength 0.23
- Jennifer Yon-Li Wo · 1 shared paper, 2026 · strength 0.23
- Keith D. Lillemoe · 1 shared paper, 2026 · strength 0.23
- Amol Kumar Narang · 1 shared paper, 2026 · strength 0.23
- Evan R. Abt · 1 shared paper, 2026 · strength 0.21
- Shineui Kim · 1 shared paper, 2026 · strength 0.21
- Michael K. Srienc · 1 shared paper, 2026 · strength 0.21
- Caius Gabriel Radu · 1 shared paper, 2026 · strength 0.21
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.